FDA clears first OTC glucose monitor for children: what families should know
The FDA’s June 12 clearance expands an over-the-counter glucose monitor to children ages 2 and older who do not use insulin. It may make glucose tracking easier for some families, but it still has important limits on low-sugar warnings, insulin use, dialysis, and insurance coverage.
On June 12, 2026, the FDA cleared the first over-the-counter continuous glucose monitor for children and other users ages 2 and older who do not use insulin. The product is Dexcom’s Stelo Glucose Biosensor System. For some families, that means one less barrier to buying a CGM, but it does not mean the device fits every child or every diabetes situation.
The biggest limitation is safety. Stelo is not for children who use insulin, not for people with problematic hypoglycemia, and not for people on dialysis. The FDA also says children should use it with adult supervision and that families should not change medicine based on CGM readings without talking with a health care professional.
What the FDA cleared
FDA says the sensor can pair with a compatible smartphone, including a caregiver’s phone. Each sensor is designed to last up to 15 days, and the app displays glucose readings and trends every 15 minutes. The FDA review also notes that the device does not include glucose alarms or alerts.
That matters because this is not the same as a prescription CGM used for insulin dosing. The OTC version is meant to give families a clearer picture of glucose patterns, not to replace a clinician’s guidance for higher-risk diabetes care.
Who the device is for, and who it is not for
According to FDA, Stelo is intended for people ages 2 and older who do not use insulin. That may make it useful for some families who want to understand how meals, activity, and daily routines affect glucose patterns.
It is not meant for children or adults who use insulin, and it is not designed for people who need hypoglycemia warnings. The FDA review also says people on dialysis should not use it.
What a CGM measures and how it differs from fingersticks
A continuous glucose monitor does not measure blood glucose the same way a fingerstick meter does. Instead, it measures glucose in interstitial fluid, the fluid just under the skin. That makes it useful for spotting patterns over time, but the number can differ from a fingerstick reading.
Families should still know when a backup fingerstick check may be needed, especially if the reading does not match how the child feels, during warm-up, or if the signal is interrupted. The American Diabetes Association says people using CGM should still have access to blood glucose monitoring when CGM seems inaccurate or glucose is changing quickly.
What families may find useful about OTC access
The main advantage is convenience. A prescription is no longer required to buy the device, and a caregiver can follow the readings on a compatible phone. That may help families notice patterns they would otherwise miss.
But OTC access does not make the device a universal solution. Because Stelo does not provide alarms, it is less suitable for families who need continuous low-glucose warning features.
Main limits families should understand
Accuracy has limits. The FDA review found performance that was comparable to Dexcom’s predicate prescription CGM, but the system still estimates glucose from fluid under the skin rather than measuring blood directly.
The device is factory calibrated only, so users cannot enter fingerstick values to adjust it. The app also does not include urgent-low, low, high, or fast-rise and fast-fall alarms.
Coverage and cost: OTC does not automatically mean covered
Over-the-counter sale is not the same as insurance coverage. Coverage rules still vary by plan, and families should not assume a pharmacy purchase will be reimbursed.
Medicare’s coverage rules show why. Medicare says CGM coverage depends on specific eligibility criteria and clinician involvement. Private insurance and Medicaid can have their own rules, copays, or prior-authorization requirements.
Practical takeaways for families
- Make sure your child fits the FDA-cleared use: age 2 or older, not using insulin, and not needing hypoglycemia alerts.
- Plan for a backup fingerstick meter when the CGM reading does not match symptoms or seems off.
- Do not use the display to change medicine on your own; talk with a clinician first.
- Check the full out-of-pocket cost before buying, and ask your plan whether any part of the device is covered.
- If a child has severe symptoms, looks very ill, or may be having a glucose emergency, do not rely on the app alone; seek urgent or emergency care as appropriate.
The bottom line: this clearance expands access, but it does not replace clinical judgment, prescription CGM features, or emergency care when a child is truly sick.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
